Episode
Episode 167 - James Mackay - Co-Founder, President & CEO of Crystalys Therapeutics
- Podcast
- The BioHub - by Avetix
- Published
- May 6, 2026
- Duration seconds
- 1857
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/the-biohub-by-avetix-7252289/episodes/episode-167-james-mackay-co-founder-president-ceo-of-crystalys-therapeutics/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-biohub-by-avetix-7252289/episode-167-james-mackay-co-founder-president-ceo-of-crystalys-therapeutics.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Today’s guest is James Mackay, Chief Executive Officer of Crystalys — a biotech company tackling one of the most common yet often overlooked metabolic diseases: gout. James brings decades of experience across the biotechnology and pharmaceutical industries, including senior leadership roles and a track record of helping bring innovative therapies to market. His career spans global pharma and emerging biotech, where he’s built a reputation for translating cutting-edge science into real-world treatments. At Crystalys, James is leading the development of novel therapies designed to address gout at its root — targeting the underlying biology of uric acid crystal formation and inflammation, with the goal of delivering more effective, long-lasting solutions for patients. The company is also gaining strong momentum, having recently raised a Series A round to accelerate its research and clinical development efforts. In today’s conversation, we’ll explore James’s journey, the science behind Crystalys’ approach to gout, and what this latest funding milestone means for the future of the company.